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Abstract We investigated the effects of ß-adrenergic stimula-
tion on the activity of the endogenous cardiac sarcoplasmic 
reticulum Ca2+/calmodulin-dependent protein kinase (SRCaM 
kinase) in Langendorff-perfused rat hearts. We found that 
isoproterenol induced generation of autonomous (Ca2+-indepen-
dent) SRCaM kinase activity to 28 ± 4.4% of the total activity. 
Moreover, dephosphorylation of the autonomous SRCaM kinase 
with protein phosphatase 2A resulted in an enzyme that was 
again dependent on Ca2+ and calmodulin for its activity. 
Activation of SRCaM kinase was coupled to phospholamban 
phosphorylation and activation of the cAMP-signaling system. 
Our results suggest that the cardiac SRCaM kinase is activated 
in response to /3-adrenoceptor stimulation. This activation 
stimulates autophosphorylation at its regulatory domain and 
converts it to an active Ca2+-independent species that may be the 
basis for potentiation of Ca2+ transients in the heart. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
ß-Adrenergic stimulation of the heart is associated with 
increases in contractility and with augmentation of the rate 
of relaxation [1]. Phospholamban (PLB) is postulated to be 
the main protein involved in the transmission of cardiac ß-
adrenergic signaling, acting as an internal brake mechanism, 
allowing for rapid increases in cardiac contraction and relax-
ation [2]. PLB functions as a reversible inhibitor of the cardiac 
SR Ca2+ pump. Phosphorylation of PLB relieves the inhibi-
tion, resulting in an overall increase in the affinity of the Ca2+ 
pump for Ca2+. During ß-adrenergic stimulation, PLB is 
phosphorylated at Ser-16 and Thr-17 [3]. In vitro, PKA and 
the SR membrane-bound Ca2+/CaM-dependent protein ki-
nase (SRCaM kinase) are known to catalyze the phosphoryl-
ation of Ser-16 and Thr-17, respectively [3,4]. 
Although initially the cardiac SRCaM kinase was thought 
to be a dedicated kinase, i.e. PLB being the unique substrate, 
recent evidence suggests that it is CaM kinase isozyme, com-
posed of δ-subunits [9]. CaM kinase is a ubiquitous multifunc-
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tional protein kinase controlled by a universal second messen-
ger but relatively little is known about its specific cellular 
functions and activation in tissues other than brain [5]. This 
is true for cardiac muscle where there has been substantial 
speculation regarding roles for CaM kinase in controlling or 
modulating contractile function [6-8]. 
In addition to regulation of SR Ca2+ uptake (via PLB 
phosphorylation), the cardiac SRCaM kinase has been pro-
posed to modulate calcium release from SR [10] and the L-
type Ca2+ current [11]. Also, adenyl cyclase type III (present 
in heart) is inhibited by CaM kinase phosphorylation [12]. 
Experiments with cultured mouse myocytes, where incubation 
with KN-62 (a CaM kinase inhibitor) ceased the spontaneous 
beating which was recovered after washing with culture me-
dium [8], support the view that SRCaM kinase plays a major 
role in excitation-contraction coupling. 
A distinguishing feature of the cardiac SRCaM kinase is 
autophosphorylation which converts SRCaM kinase to an 
autonomous kinase [9]. It has been shown that Ca2+/CaM-
dependent autophosphorylation of a threonine residue within 
the regulatory domain (Thr-286/287 for the α/β-subunits of 
the neuronal CaM kinase, respectively) is responsible for the 
generation of autonomous activity [5] and that autophospho-
rylation precedes substrate phosphorylation and is required 
for full activation of the enzyme [13]. Studies in intact cells 
indicate that autophosphorylation accompanies physiological 
activation and autophosphorylation renders the kinase consti-
tutively active [14,15]. Therefore, CaM kinase autophospho-
rylation and the generation of autonomous activity are used 
as a marker for CaM kinase activation in intact cells, in re-
sponse to extracellular signals or during a cellular response 
[15-17]. 
We have exploited this approach to test whether ß-adrener-
gic agonists, such as isoproterenol, which stimulate the 
cAMP-signaling system, are functionally coupled to activation 
of SRCaM kinase in intact heart. In addition, we wanted to 
determine whether the autoregulatory properties which have 
been shown to produce a Ca2+-independent SRCaM kinase in 
vitro [9] are operational in a physiological system. We report 
for the first time activation of SRCaM kinase in the intact 
heart. Our results suggest that the cardiac SRCaM kinase 
autophosphorylates in a Ca2+/CaM-dependent manner, be-
comes Ca2+-independent and phosphorylates PLB at Thr-17 
in response to ß-adrenergic stimulation. 
2. Materials and methods 
2.1. Materials 
Isoproterenol and secondary antibody (peroxidase-conjugated) 
mouse IgG were from Sigma. Secondary antibody (peroxidase-conju-
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gated) rabbit IgG was from Dianova. Biotinylated calmodulin was 
from Gibco-BRL, Life Technologies. Okadaic acid from Calbiochem. 
The Vectastain ABC kit was a product of Vector Labs (USA). Anti-
phospholamban (mouse), IgGl, from Biomol. Phosphorylation site-
specific antibodies PS-16 and PT-17 [18] were from Phosphoprotein 
research ELFORDLEA (UK). The phospholamban synthetic peptide 
PLB-24, calmodulin, rat forebrain CaM kinase and protein phospha-
tase 2A, from rabbit skeletal muscle, were as in [9]. Phosphorylase b 
and phosphorylase kinase as in [19]. All other materials as in [9]. 
2.2. Heart per fusions 
Hearts from anesthetized (30 mg/kg sodium phenobarbital) and 
heparinized (500 U/kg) male Wistar rats (200-400 g body weight) 
were excised and cannulated for retrograde aortic perfusión with a 
modified Krebs-Henseleit solution containing (mM) NaCl 118, KC1 
4.7, CaCl2 1.5, MgS04 1.2, NaHC0 3 25, Na2EDTA 0.05, KH 2P0 4 
0.23 and glucose 11.1. The solution was saturated with 95% 02 /5% 
C0 2 pH 7.4. The perfusión apparatus and the corresponding software 
were from Hugho-Sachs Electronic (Germany). Systolic pressure was 
measured with a latex balloon, filled with ethanol/H20 which was 
inserted into the left ventricle through the left atrium via a catheter 
to an Isotec transducer. The pressure in the balloon was set from 14-
18 mm Hg. Signals were recorded on a Linearcorder mark 8WR3500. 
The recorded functional parameters were left ventricular pressure 
(LVP), +dp/dt, —dp/dt and coronary flow. The stimulation frequency 
was fixed at 340 beats/min. The perfusión was carried out at 37°C 
with a constant aortic pressure of 60 mm Hg. After a stabilizing 
period of 30 min (10 min without and 20 min with electrical stimula-
tion), isoproterenol was added into the perfusión cannula by an in-
fusion pump. The final concentration of the isoproterenol applied 
(1 μΜ) was calculated by the flow rate. In control hearts, isoproter-
enol was omitted. After 2 min perfusión, the hearts were freeze-
clamped with pre-cooled (— 196°C) Wollenberger clamps [20], pulver-
ized with a pre-cooled mortar and pestle and stored under liquid 
nitrogen for further analysis. 
2.3. Membrane vesicle preparation 
Sarcoplasmic reticulum-enriched microsomal fractions were pre-
pared according to previously published procedures [9,21] with minor 
modifications. Separate membrane vesicle preparations were made 
from each heart. All procedures were carried out at 4°C. Shortly, 
the powdered tissue from each heart was thawed and homogenized 
simultaneously in 6 vols. of sucrose 290 mM, NaN3 3 mM, imidazole-
HC1 10 mM pH 6.9, dithiothreitol 5 mM, NaF 10 mM, phenylmeth-
ylsulfonyl fluoride 0.2 mM, EDTA 2 mM, Na 4 P 2 0 7 20 mM, leupeptin 
2 mg/1, soyabean trypsin inhibitor 8 mg/1 and okadaic acid 1 μΜ, 3 X 
for 30 s with a Polytron (Brinkmann Instruments). The homogenate 
was centrifuged at 4000 Xg for 15 min. The supernatant was filtered 
2X through glasswool and the filtrate was centrifuged at 14000Xg 
for 15 min. The final supernatant was sedimented at 120000Xg for 60 
min. The soft pellet obtained was suspended in 650 mM KC1, 10 mM 
imidazole pH 6.8, 10 mM Na4P2Cv, okadaic acid 1 μΜ and incubated 
on ice for 60 min. The suspension was centrifuged first at 14000Xg 
for 10 min and then at 120000Xg· for 60 min. The resulting pellet-
containing sarcoplasmic reticulum vesicles was re-suspended in a small 
volume of 10 mM Hepes pH 7.2, 0.29 M sucrose, 0.5 mM EDTA, 
0.1 M KC1, okadaic acid 1 μΜ and stored in liquid nitrogen. 
2.4. Renaturation of SR proteins and in situ autophosphorylation 
Fractionated SR membrane proteins transferred from SDS-PAGE 
to Immobilon membranes were denatured in situ with guanidine-HCl 
(7 M), renatured overnight (20 h at 4°C) in a buffer containing NP-40 
(0.1% v/v) and autophosphorylated with [γ-32Ρ]ΑΤΡ, 10 μθ /piύ , in the 
presence or absence of Ca2+/CaM, as described in [22]. Throughout 
the procedure, care should be taken that the membrane does not 
become dry and it is always kept in solution. Autophosphorylation 
was detected by autoradiography using an intensifying screen at 
—70°C for « 2 2 h. Autoradiographs were scanned using a PDI 
(USA) densitometer with The Discovery Series software. 
2.5. Phosphorylation of PLB-peptide following in situ renaturation 
Blotted SR membrane proteins were denatured and renatured (as 
above) and the membrane piece corresponding to 54-52 kDa (~0.6 
cm2) was excised and blocked for 1 h with 5% BSA in 30 mM Tris-
HC1 pH 7.5. Next, it was placed into a microcentrifuge tube with 
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40 mM Hepes buffer pH 7.3. The buffer was removed and the 
SRCaM kinase activity was assayed using a synthetic phospholam-
ban-like peptide, PLB-24, as substrate (50 μΜ), with 70 μΐ of assay 
mixture as described in [9]. The reaction temperature was 30°C and 
after 15 min 60 μΐ of the reaction mixture were spotted onto phos-
phocellulose P-81 paper and the sample was processed for scintillation 
counting. 100% activity is defined as that determined in presence of 
Ca2+/CaM (total activity) for SRCaM kinase from control hearts, and 
corresponds to 45 nmol Pi/min/mg of blotted SRCaM kinase (after in 
situ denaturation and renaturation). To determine the amount of 
SRCaM kinase present in the 54—52 kDa blot, CaM-binding assay 
was performed and the peak area of the signal was quantified by 
densitometry (O.D. relative units). The corresponding amount of pro-
tein was determined from a standard curve (jig of purified rat fore-
brain CaM kinase vs. O.D. relative units from CaM-binding assays). 
2.6. Dephosphorylation of blotted SRCaM kinase from Iso-hearts 
Blotted SR membrane proteins from isoproterenol-stimulated 
hearts were in situ denatured and renatured and the piece of the 
membrane corresponding to 54-52 kDa was excised from the lane, 
blocked with BSA and placed into a microcentrifuge tube with 40 mM 
Tris-HCl pH 8.0, 5% ethylene glycol (v/v), 1 mg/ml BSA (buffer A) 
and PP2A (10 U/ml). Control incubations received phosphatase dilu-
tion buffer (50 mM Tris-HCl pH 7.0, 30 mM dithiothreitol, 20 mM 
caffeine, 1 mg/ml BSA) instead of PP2A. Reaction time was 2 min at 
30°C, the reactions were terminated with 50-fold dilution into ice-cold 
buffer A and the blot was washed 2 X with excess of 40 mM Hepes 
buffer pH 7.3 and used for peptide PLB-24 phosphorylation (as 
above). 
2.7. Immunoblotting of phospholamban 
SR membrane proteins were solubilized in sample buffer [23] and 
boiled at 95°C for 5 min (to completely dissociate PLB into its mono-
mers). 20 μg of SR proteins were fractionated on a urea/SDS gel 
system [23] electrotransferred onto PVDF membranes and probed 
with the general anti-PLB monoclonal antibody (IgGl) [24]. For 
site-specific discrimination of PLB phosphorylation, the phosphoryla-
tion site-specific antibodies PS-16 and PT-17, raised against PLB-
phosphorylated peptides [18], were used (at 1 : 10000 dilution) accord-
ing to manufacturer's recommendations. 
2.8. Other methods 
Tissue levels of cAMP were determined as in [23]. The phospho-
rylase b to a transformation (% of total activity) was estimated as in 
[25], Activities of PKA were analyzed by a modified method of Mur-
ray et al. [26]. CaM-binding assays were performed as in [27], using 
0.5 μg/ml biotinylated CaM in the presence of 1 mM CaCl2. Bound 
CaM was visualized using Vectastain ABC reagents and the ECL 
detection kit. Protein concentration was determined by the Biorad 
protein-binding assay using γ-globulin as standard. 
3. Results and discussion 
The present study was undertaken as a first approach to-
ward assessing the activation of S R C a M kinase in intact beat-
ing hearts following isoproterenol stimulation (1 μ Μ for 
2 min). In order to accurately measure the autophosphoryla-
tion state of S R C a M kinase in vivo, control and Zso-hearts 
were freeze-clamped with Wollenberger clamps and cardiac 
SR membrane proteins were prepared in a homogenization 
medium that preserves the endogenous protein-phosphoryla-
tion state [14]. Next, the technique of in situ denaturat ion and 
renaturation of blotted SR membrane proteins was employed 
to assess S R C a M kinase substrate phosphorylation and auto-
phosphorylation activities. Using this technique, we circum-
vent potential pitfalls associated with measurement of C a M 
kinase activities in crude lysates: (i) contributions from over-
lapping (in substrate specificity) Ca 2 + /CaM-dependent protein 
kinases; and (ii) artifactual activities that reflect alterations 
which occurred during the assaying procedure, i.e. activity 
modulat ion by cellular components (kept apart in vivo) car-
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Fig. 1. In situ denaturation, renaturation and autophosphorylation 
of blotted cardiac SR proteins. SR membrane proteins from isopro-
terenol stimulated (1 μΜ, for 2 min) rat hearts (lanes 3 and 4) and 
control hearts (lanes 1 and 2) were prepared as described in Section 
2. Next, they were fractionated on 10% SDS-PAGE (50 μ&^ηβ), 
electrotransferred to Immobilon-P membranes and were in situ de-
naturated and renaturated. The blots were incubated with kinase re-
action buffer with [γ-32Ρ]ΑΤΡ in presence (lanes 1 and 3) or absence 
(lanes 2 and 4) of Ca2+/calmodulin. Autophosphorylation was de-
tected by autoradiography and peak areas were quantified (O.D.) by 
densitometry. 
ried through the assaying procedure. The latter complication 
is of particular concern in cardiomyocyte lysates where intra-
cellular compartments/structures maintain compartmentation 
of second messengers and responses to them [28]. 
As shown in Fig. 1, SRCaM kinase from stimulated hearts 
(lanes 3 and 4) exhibits Ca2+/CaM-dependent and Ca2+/CaM-
independent autophosphorylation while, under similar condi-
tions, SRCaM kinase from non-stimulated hearts (lanes 1 and 
2) autophosphorylates only in a Ca2+/CaM-dependent man-
ner. Quantitation by densitometry of the level of in situ au-
tophosphorylation on the blot indicates that isoproterenol 
stimulation induces: (i) decrease of the Ca2+/CaM-dependent 
autophosphorylation activity (lane 3, 65% of lane 1, _Ρ<0.05, 
n = 3 separate SR preparations); and (ii) generation of signifi-
cant Ca2+/CaM-independent autophosphorylation activity 
(lane 4, 210% of lane 1, P<0 .05 , « = 3, as above). Immuno-
reaction of lanes 1 and 3 from Fig. 1 (control and /so-treated 
SR membrane proteins) with the CK2-DELTA antibody, spe-
cific for δ-isoforms of CaM kinase [9,15], indicates similar 
SRCaM kinase protein levels for control and Zso-SRCaM 
kinase (not shown). 
Next, SRCaM kinase activity was measured as incorpora-
tion of phosphate into exogenous PLB-24 peptide, a good 
substrate for the cardiac SRCaM kinase [4,9]. Control and 
isoproterenol-treated SR proteins were in situ denatured, re-
natured and the piece of the membrane corresponding to 
SRCaM kinase (54-52 kDa) was used to phosphorylate the 
PLB-24 peptide. In Fig. 2, ho, it is shown that isoprotenol-
treated SRCaM kinase has become Ca2+/CaM-independent to 
28 ± 4.4% of the total activity. Using syntide-2 as substrate, 
similar increase in autonomous activity was obtained. The 
slight decrease in total activity, 81.2 ±6.2% for Zso-SRCaM 
kinase (Fig. 2), is due to thermal instability of the autophos-
phorylated SRCaM kinase (Dr. H. Schulman, personal com-
munication and [9]). To provide further evidence that the 
Ca2+-independent form of SRCaM kinase was generated by 
autophosphorylation rather than due to other post-transla-
tional modifications, the effect of PP2A on this enzymatic 
activity was examined using SRCaM kinase from stimulated 
hearts. We found that PP2A treatment reduced the Ca2+-in-
dependent activity to 8± 1.8% of the total activity while the 
Ca2+-independent activity of SRCaM kinase from control 
hearts was 4.5 ± 0.8%. (Fig. 2, PP2A and Control). It might 
be argued that incomplete dephosphorylation can be due to 
steric hindrance, resulting from immobilization of SRCaM 
kinase on the membrane. Thus, we propose that autophos-
phorylation is responsible for the Ca2+-independent activity, 
Table 1 
Consequences of ß-adrenergic stimulation in Langendorff-perfused rat myocardium 
A 
Experimental groups 
Control 
Isoproterenol 
cAMP (pmol/mg of 
4.49 ±0.49 (5) 
14.40 ±2.71 (3) 
protein) Phosphorylase a 
8.03 ±1.18 (4) 
56.80 ±2.20 (3) 
PKA activity (-
Cytosolic 
0.08 ±0.01 (5) 
0.54 ±0.04 (4) 
-cAMP/+cAMP) 
Particulate 
0.24 ±0.05 (5) 
0.37 ± 0.03 (4) 
B 
; (min) 
0 
2 
+dp/di (mm Hg/s) 
1245 ±79 
4615±217 
—dp/di (mm Hg/s) 
943 ±47 
4119 ±166 
LVP (mm Hg) 
53.3±3.3 
186.7 ±7.6 
Coronary flow (ml/min) 
7.6± 1.4 
12.4 ±1.3 
Table A: Effects of isoproterenol stimulation on the cAMP-signaling system. Rat hearts were stimulated with isoproterenol (1 μΜ, for 2 min) as 
described in Section 2. Control hearts were perfused under similar conditions in absence of isoproterenol. Hearts were freeze-clamped and the 
biochemical parameters were determined in control and isoproterenol-stimulated hearts. The PKA activity is expressed as the ratio of malantide 
phosphorylation in the presence and absence of 2.8 μΜ cAMP. Values represent means ± S.E.M. Numbers in parentheses indicate independent 
experiments (tissue sample for one experiment was from 1 heart). 
Table B: Effects of isoproterenol stimulation on hemodynamics. Rat hearts were stimulated with 1 μΜ isoproterenol as described in Section 2. 
Stimulation frequency was fixed at 340 beats/mm. Isoproterenol infusion (2 min) was initiated after a stabilizing period of 30 min (t = 0 min). 
Inotropy and rate of relaxation were measured from the first derivatives of LVP (+dp/d/ and —dp/di, respectively). Values represent means 
± S.E.M. of at least 4 hearts. 
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Fig. 2. Phosphorylation of the peptide PLB-24 by renaturable SRCaM kinase from control hearts, Zso-hearts, and by renaturable /so-SRCaM 
kinase dephosphorylated in vitro. Following in situ denaturation and renaturation of blotted SR proteins (70 μg/lane) from control and Iso-
hearts, the piece of the blot corresponding to the SRCaM kinase (54-52 kDa) was excised from the lane, blocked with BSA, and (1) incubated 
in an assay mixture with peptide PLB-24 in presence (open bars) or absence (solid bars) of Ca2+/CaM or (2) the Zso-SRCaM kinase was 
treated with PP2A (10 U/ml) and sequentially assayed for peptide PLB-24 phosphorylation (PP2Á). 100% activity is the activity in presence of 
Ca2+/calmodulin of renaturable SRCaM kinase from control hearts as described in Section 2. Values are means ± S.D. of three determinations 
(representing three different hearts). Duplicate aliquots (70 μg) from control and /so-hearts were analyzed by in situ renaturation and phospho-
rylation as in Fig. 1 to confirm the presence of SRCaM kinase in the 54-52 kDa area (left side of Fig. 2). 
in particular within the regulatory domain, i.e. Thr-287, since 
the other putative sites for autophosphorylation (Thr-306 and 
Ser-315) are protected in vivo by the bound calmodulin. 
In vitro, the active, autonomous SRCaM kinase (or neuro-
nal CaM kinase) can autophosphorylate in absence of Ca2+/ 
CaM at sites that become accessible following dissociation of 
CaM from the holoenzyme, i.e. Ser-314/315, Thr-305/306 for 
a/ß-subunits [9,27]. In agreement, our data suggest that the 
observed large Ca2+/CaM-independent autophosphorylation 
activity (Fig. 1, lane 4) is at sites masked by CaM in intact 
heart and the limited Ca2+/CaM-dependent autophosphoryl-
ation activity (Fig. 1, lane 3) mostly reflects the pool of 
SRCaM kinase molecules which were not autophosphorylated 
in vivo at the autonomous site. 
Immunoblots of SR membrane proteins from control and 
stimulated hearts with the antibodies PS-16 or PT-17 (discrim-
inating between PLB phosphorylated at Ser-16 or Thr-17, 
respectively) showed that PLB from Zyo-hearts was phos-
phorylated at Thr-17 and Ser-16 (Fig. 3, lanes 1 and 2, re-
spectively). Under similar exposure times, PLB from control 
hearts did not react with the antibodies PS-16 and PT-17 (not 
shown). Phosphorylation of PLB at Ser-16 has been postu-
lated to be mediated by PKA, reflecting activation of the 
cAMP-signaling system in response to ß-agonist stimulation 
[3,23]. In agreement, we found that in /so-hearts: cAMP levels 
and PKA activities (cytosolic and particulate) were elevated 
(Table 1A). Also, the phosphorylase b to a conversion was 
increased (Table 1A), reflecting acceleration of glycogenolysis 
in response to higher energy demands due to enhanced con-
tractility (Table IB). 
The protein kinase, which is known to catalyze in vitro 
phosphorylation of the Thr-17 site of PLB, is CaM kinase 
[4,9]. The cytosolic cardiac CaM kinase could not be the 
physiologically relevant kinase for the Thr-17 site of PLB 
since (i) it has Km for PLB in the micromolar range [29], (ii) 
kinase and substrate exist in the heart in submicromolar 
amounts, implying that Kmax conditions would not exist in 
the intact cell, unless we assume localization of these two 
proteins in the same subcellular compartment, e.g. sarcoplas-
mic reticulum. Therefore, we propose that phosphorylation of 
PLB at Thr-17 is mediated mostly by SRCaM kinase. Acti-
vation of SRCaM kinase reflects increase in intracellular Ca2+ 
levels. The nature of calcium that activates CaM kinase in 
intact cells can be either from influx through the L-type 
Ca2+ channel [16,30] or from intracellular Ca2+ pools 
[15,31]. Stimulation of ß-adrenoceptors leads to an enhanced 
calcium influx which is the result of PKA-mediated phospho-
rylation of the L-type Ca2+ channel [32]. Experiments with 
verapamil, a Ca2+ channel blocker, showed that verapamil 
treatment of isoproterenol-stimulated cardiac myocytes re-
sulted in large reduction of PLB phosphorylation levels [33]. 
This indicates that Ca2+ influx through the L-type Ca2+ chan-
nel is required for activation of the cardiac SRCaM kinase. 
Interestingly, Thr-17 PLB phosphorylation in the intact heart 
requires elevated tissue cAMP levels; conditions that increase 
Ca2+ but do not augment cAMP fail to produce PLB phos-
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Fig. 3. Immunoblotting of cardiac SR proteins from /so-stimulated 
hearts with phosphorylation site-specific antibodies against PLB 
phosphorylated at Ser-16 or Thr-17. SR membrane proteins from 
/io-hearts (20 μg/lane) were separated on an urea/SDS gel system, 
electrotransferred to membranes, and probed for immunoreaction 
with the antibodies PT-17 (lane 1) or PS-16 (lane 2), discriminating 
between PLB phosphorylated at Ser-16 or Thr-17, respectively. Lane 
3 was probed with the general anti-PLB monoclonal antibody (not 
discriminating between phospho and dephospho-PLB) to indicate 
the position of the PLB monomer. 
phorylation at Thr-17 [3,7]. Several studies support the view 
that in intact heart the PPs are active. Incubation of ventric-
ular cardiomyocytes with okadaic acid (a PP1 and PP2A in-
hibitor) increased the phosphorylation of PLB and troponin I 
[33,34] while termination of isoproterenol infusion of intact 
hearts results in dephosphorylation of PLB and troponin I 
[35]. Omitting PP inhibitors from the media during cardiac 
SR vesicle preparation greatly reduced the levels of autono-
mous SRCaM kinase activity and phosphate incorporation 
into Thr-17 of PLB (personal observation). It has been shown 
that the major cardiac SR-PP (70%) is PP1 type [36]. Stimu-
lation of intact hearts with isoproterenol increased inhibitor-1 
activity (inhibitor of PP1) and reduced drastically SR PP1 
activity [37]. It is known that PP1 dephosphorylates and de-
activates the autonomous CaM kinase [38]. Thus, increase in 
Ca2+ alone would not result in activation of SRCaM kinase 
and PLB phosphorylation since the SR-PP 1 is active in the 
intact heart and dephosphorylates the kinase. Therefore, the 
ß-adrenoceptor-induced increase in cAMP, which probably 
leads to PKA-mediated inhibition of the SR-PP 1, is required 
for the activation of SRCaM kinase to become manifest as 
PLB phosphorylation at Thr-17. Talosi et al. found that, after 
termination of ho infusion of intact hearts, PLB was dephos-
phorylated but the rate of Ser-16 dephosphorylation (which 
correlated with decreases in cAMP levels) was faster than the 
Thr-17 dephosphorylation [35] although the PLB-PP dephos-
phorylates with the same efficiency phospho-Ser or phospho-
Thr in PLB. These results comply with our data: the finding 
that Thr-17 remains phosphorylated for a longer period re-
flects SRCaM kinase phosphorylation in the autonomous 
mode and supports a role for SRCaM kinase autophospho-
rylation in short-term potentiation of the Ca2+ signal in the 
heart. 
PP2A and PP2C (a Mg2+-dependent PP) are the other two 
SR-PPs (30%) [36]. Both PP2A and PP2C in vitro dephos-
phorylate and deactivate the autophosphorylated SRCaM 
kinase/CaM kinase [9,39]. Since okadaic acid alone does not 
completely inhibit the dephosphorylation of SRCaM kinase 
(personal observation) and additional PP inhibitors are re-
quired, we propose that all three PPs are involved in the intact 
heart. Further studies are required to examine the particular 
contributions of the SR PP2A and PP2C (in addition to PP1) 
in the reversal of the cellular functions induced by the auto-
phosphorylation of SRCaM kinase as well as how the syner-
gistic actions of the two second messengers (cAMP and Ca2+) 
result in inhibition of SR-PPs during ß-adrenergic signaling. 
In conclusion, our study identifies the cardiac SRCaM ki-
nase as one of the targets of ß-adrenergic stimulation. We 
propose that the mechanism of activation of the cardiac 
SRCaM kinase in response to ß-adrenergic stimulation in-
volves Ca2+ influx through the L-type Ca2+ channel and con-
comitant inhibition of the SR-PP1 activity (by cAMP-depend-
ent mechanisms) that results in SRCaM kinase activation to 
become evident. The activated SRCaM kinase autophospho-
rylates within the regulatory domain and becomes Ca2+-inde-
pendent. One manifestation of this activation is phosphoryla-
tion of PLB at Thr-17 which contributes to further increase in 
myocardial relaxation. 
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